Clinical-reference tools answer different questions. Epocrates provides US-centred drug information, eMC provides current product-specific UK SmPCs, and iatroX provides cited clinical synthesis plus an adaptive GPhC Q-bank. UK pharmacists may also need NICE, SPS, local guidance or specialist support.
Epocrates
Epocrates provides drug monographs, interaction checking, pill identification and clinical content, primarily for the US market.
Strengths for pharmacists: Fast drug lookups. Interaction checker. Pill identification feature (useful for community pharmacy). Clean mobile interface. Free tier available.
Limitations: It defaults to US labels, brands and dosing conventions. UK pharmacists must verify UK product particulars in the relevant SmPC on eMC and use applicable UK guidance for recommendations and implementation.
Best for: Pharmacists who also work internationally or need US drug data. Not recommended as a primary UK clinical reference.
eMC (SmPCs)
eMC provides free access to current, product-specific UK SmPCs, including licensed indications, dosing, contraindications, interactions, adverse reactions and excipients. It is a web source of regulatory product information, not a condition-led clinical-reference app.
Strengths: UK product-specific information that lets clinicians verify the exact medicine, strength and formulation. SmPCs are maintained by the relevant marketing-authorisation holders and published on eMC.
Limitations: SmPCs are product-led regulatory documents, not natural-language clinical guidance or independent interaction-management advice. Add NICE, SPS, local or specialist guidance when the question concerns treatment choice or implementation.
Best for: Verifying the licensed particulars of the exact UK product before prescribing, dispensing or counselling.
iatroX
iatroX provides two tools relevant to pharmacists as a clinical reference:
Ask iatroX returns cited answers grounded in NICE, CKS and SIGN guidance, with medicines information from relevant SmPCs on eMC.
GPhC Q-Bank — 1,000+ adaptive questions mapped to the CRA blueprint. For trainee pharmacists, this is integrated exam preparation alongside the clinical reference. For qualified pharmacists, it is CPD-ready knowledge testing.
Strengths: Cited UK clinical synthesis, natural-language queries, an adaptive GPhC Q-bank and mobile access. iatroX is registered with the MHRA as a Class I medical device.
Limitations: iatroX is not a substitute for the exact SmPC, a specialist interaction database, the local formulary or professional judgement. Open and verify the cited source before acting.
| Feature | Epocrates | eMC (SmPCs) | iatroX |
|---|---|---|---|
| Primary jurisdiction | US | UK product information | UK-oriented clinical synthesis |
| Natural-language clinical Q&A | No | No | Yes (Ask iatroX) |
| Product information | US drug monographs | UK product-specific SmPCs | Cited medicines information from relevant SmPCs |
| GPhC Q-bank | No | No | Yes (adaptive) |
| Access | Freemium | Free web access | Free Ask tier; paid Q-bank |
| Mobile access | Yes | Browser | iOS and Android |
Recommended stack: eMC for exact UK product information + Ask iatroX for cited clinical synthesis + applicable NICE, SPS or local guidance + the iatroX GPhC Q-Bank for CRA revision.